FDA Approves Higher-Dose Wegovy at 7.2mg for Weight Loss

The U.S. Food and Drug Administration has approved a new 7.2 mg dose of Wegovy (semaglutide) injection for weight loss and long-term weight maintenance in certain adult patients, according to an FDA press release issued today. The approval represents the fourth product approved under the FDA's National Priority Voucher Program.

The new 7.2 mg dose extends Wegovy's current dosing options, which previously topped out at 2.4 mg weekly injections. Semaglutide is already available in multiple formulations across different indications, with lower doses used for diabetes management under the brand name Ozempic, while Wegovy has been the dedicated weight loss formulation since its 2021 approval.

The FDA's use of the National Priority Voucher Program for this approval signals recognition of significant unmet medical needs in weight management treatment. This expedited review pathway is designed to accelerate access to treatments addressing critical health priorities. However, the FDA announcement provided limited details about clinical trial data, safety profiles, or specific patient eligibility criteria beyond stating the product is intended for "certain adult patients."

The approval comes as demand for GLP-1 receptor agonists continues to surge, with existing Wegovy doses frequently experiencing supply constraints. The higher 7.2 mg dose could provide an additional treatment option for patients who may need more intensive intervention or have not achieved optimal results with current dosing. The FDA has not indicated when the new dose will become commercially available or provided guidance on how healthcare providers should integrate this option into existing treatment protocols.

Patients currently using Wegovy or considering semaglutide for weight management will need to work with their healthcare providers to determine if the higher dose formulation is appropriate once it becomes available. The timing and eligibility requirements for accessing the 7.2 mg dose will depend on additional prescribing information that has not yet been released by the FDA or manufacturer.